Intco Medical Technology stock: Price History and Returns
300677.SZIntco Medical Technology's share price rose by 1% a year over the last 5 years, 5% in total (in CNY). With dividends reinvested the return was +2% a year, +10.4% in total. The dividend yield is 0.42% today.
This shows what Intco Medical Technology Co., Ltd. has returned on the stock market in the past. Past returns say nothing about the future.
Daily figure as of 20 Nov 2026
Share Price Since 2017
How Intco Medical Technology Has Performed
The stock has not yet recovered its largest drawdown of 89% between January 2021 and February 2024 and trades 70.1% below the high today. In its best year, 2020, the share price more than doubled at +1,421%, the weakest was 2022 at −56.4%. 2025 was a strong year for the stock at +53.9%, against an average of +1% a year over the last 5 years. Since the low in February 2024 the share price has risen more than twofold.
3 of 8 full calendar years since 2018 ended with a loss. The longest run of gains lasted from 2023 to 2025, three years in a row. From 2021 to 2022 the stock fell two years in a row. Dividends added about 1 percentage point a year over 5 years. Since the start of the year the stock is up 23.9%.
How Intco Medical Technology Compares
Over 5 years Intco Medical Technology trailed the MSCI World: with dividends +1.1% a year against +9.5% for the index, in US dollars. Over one year, Intco Medical Technology did better than 66% of the 44 other stocks in the Medical (Instruments & Supplies) industry. Over five years the figure was 76%. The highest share price returns over five years in the Medical (Instruments & Supplies) industry came from Bonesupport Holding, Pulse Biosciences and Asahi Intecc.
| Period | Intco Medical Technology | MSCI World |
|---|---|---|
| 1 year | +32.5% | +10.8% |
| 5 years | +1.1% | +9.5% |
Returns of Industry Peers
Among its industry peers, Teleflex led over one year (+54.6%) and Stevanato Group trailed furthest (−25.4%).
| Stock | 1 year | 5 years |
|---|---|---|
| Teleflex | +54.6% | −48.8% |
| Gan & Lee Pharmaceuticals. | −0.2% | −7.2% |
| Merit Medical Systems | +0.9% | +21.9% |
| ICU Medical | +32.6% | −28.8% |
| Stevanato Group | −25.4% | −30.8% |
What Became of $1,000
$1,000 invested in Intco Medical Technology 5 years ago is worth $1,005 today, $1,056 with dividends reinvested.
With dividends means each dividend is reinvested at the closing price on the ex-date, before taxes and costs. The index is represented by an accumulating ETF, dollar amounts at ECB rates. Industry figures are share price returns only, in each exchange's currency, as of 20 Nov 2026.
Returns by Period
| Period | Total | Per year |
|---|---|---|
| 1 year | +23.9% | +23.9% |
| 3 years | +128.9% | +31.8% |
| 5 years | +5% | +1% |
| Since 2017 | +785.8% | +26.3% |
Returns by Calendar Year
Figures as a table
| Year | Closing price | Return |
|---|---|---|
| 2026 to date | $7.23 | +23.9% |
| 2025 | $5.84 | +53.9% |
| 2024 | $3.79 | +8.2% |
| 2023 | $3.50 | +11.1% |
| 2022 | $3.15 | −56.4% |
| 2021 | $7.23 | −48.4% |
| 2020 | $14.01 | +1,421% |
| 2019 | $0.92 | +19.6% |
| 2018 | $0.77 | −47.2% |
Peak Price and Largest Drawdown
This is the pure share price return in CNY from closing prices, adjusted for stock splits. Dividends come on top and are not included here.
Work out your own amount and period in the What-if calculatorData and Required Disclosures
- ; time horizon around 12 months
- Rated Weak since 7 Nov 2026; valuation signal Fairly valued since 20 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
